PTC shares soar on EU backing for muscular dystrophy drug

LONDON (Reuters) - Shares in U.S. biotech company PTC Therapeutics more than doubled in premarket dealings on Friday after European regulators recommended a conditional marketing authorization for Translarna, its drug for Duchenne muscular dystrophy. European Medicines Agency experts had adopted a negative opinion on the drug in January. Conditional marketing authorization is an early access mechanism for medicines that address an unmet medical need for patients suffering from life-threatening diseases, even if comprehensive clinical data are not yet available. ...



via Health News Headlines - Yahoo News http://ift.tt/1r0sCZO